MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.035
+0.015
+0.50%
Opening 09:34 06/21 EDT
OPEN
3.050
PREV CLOSE
3.020
HIGH
3.090
LOW
3.021
VOLUME
167.67K
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
0.5603
MARKET CAP
309.04M
P/E (TTM)
-5.3395
1D
5D
1M
3M
1Y
5Y
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap. In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of May 24th – 30th, 2021.
Benzinga · 06/02 14:36
Thinking about buying stock in Stealth BioTherapeutics, BlackBerry, Ideanomics, Seelos Therapeutics, or Altimmune?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MITO, BB, IDEX, SEEL, and ALT.
PR Newswire - PRF · 06/02 13:33
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2021
 
Benzinga · 06/01 14:04
Thinking about buying stock in Akebia Therapeutics, BlackBerry, Seelos Therapeutics, Canopy Growth Corp, or Aqua Metals?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKBA, BB, SEEL, CGC, and AQMS.
PR Newswire - PRF · 06/01 13:31
BRIEF-Seelos Therapeutics Inc Announces Its Inclusion In First U.S. Listed Exchange Traded Fund (ETF) Focused On Psychedelics
reuters.com · 06/01 13:00
Seelos Therapeutics Announces its Inclusion in the First U.S. Listed Exchange Traded Fund (ETF) Focused on Psychedelics
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been included in the Defiance Next Gen Altered ...
PR Newswire · 06/01 12:00
Cantor Fitzgerald Initiates Coverage On Seelos Therapeutics with Overweight Rating, Announces Price Target of $10
Cantor Fitzgerald initiates coverage on Seelos Therapeutics (NASDAQ:SEEL) with a Overweight rating and announces Price Target of $10.
Benzinga · 06/01 11:20
--Cantor Fitzgerald Initiates Coverage on Seelos Therapeutics With Overweight Rating, $10 Price Target
MT Newswires · 06/01 07:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SEEL. Analyze the recent business situations of Seelos Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SEEL stock price target is 9.80 with a high estimate of 15.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 86
Institutional Holdings: 25.26M
% Owned: 24.81%
Shares Outstanding: 101.83M
TypeInstitutionsShares
Increased
13
2.52M
New
46
16.54M
Decreased
7
635.48K
Sold Out
6
893.86K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.19%
Pharmaceuticals & Medical Research
-0.98%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
Raj Mehra
Chief Scientific Officer
Warren Wasiewski
Director
Judith Dunn
Director
Brian Lian
Director
Daniel O'Connor
Director
Richard Pascoe
No Data
About SEEL
Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).

Webull offers kinds of Seelos Therapeutics Inc stock information, including NASDAQ:SEEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SEEL stock methods without spending real money on the virtual paper trading platform.